These findings are critical for optimizing the management of higher-risk MDS patients and the selection of HMA therapy or prompt consideration for molecularly defined clinical trials, such as novel therapies targeting BCL-2, IDH1/IDH2, or FLT-3 or allogeneic transplantation for fit patients. This evidence concerns the gene FLT3 and myelodysplastic syndrome.